Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
According to Janet Woodcock, 63 drugs have been given the “QIDP” designation so far. Our inofficial list has 61 drugs, of which we believe only 57 are still in active clinical development. So we are in fairly close agreement. That may seem like an impressive record but it is also Continue reading QIDP Drug Update – Part 2: Categories of Interest
>>> For the latest QIDP list, please click HERE <<< Since our last QIDP blog from April 8, 2015, several new drugs have made the list which now includes 41 compounds. Below a table which includes compound, sponsor and development stage (Phase). It also indicates whether a drug has been the topic of a Continue reading QIDP Drugs – 4th Edition
Besides azoles, candins and the polyene class of antifungals there is not much to select from when it comes to systemic fungal infections. Until the recent arrival of voriconazole and posaconazole, infections caused by molds always required amphotericin B to control. Only for Candida several good treatments exist on the Continue reading Nikkomycins Are Finally Getting Some Respect